坦索罗辛联合索利那新在治疗轻中度良性前列腺增生合并膀胱过度活动症中的应用

Application of Tamsulosin Combined with Solifenacin in Treatment of Mild and Moderate Benign Prostatic Hyperplasia Complicated with Overactive Bladder

目的:探讨坦索罗辛联合索利那新在治疗轻中度良性前列腺增生伴膀胱过度活动症(OAB)的有效性及安全性。方法:选取2015年6月-2016年10月本院收治的68例轻中度良性前列腺增生合并膀胱过度活动症患者作为研究对象,随机分为对照组和观察组,各34例。观察组采用坦索罗辛(0.2 mg,qd)联合索利那新治疗(0.5 mg,qd)治疗,对照组单纯采用坦索罗辛(0.2 mg,qd)治疗。观察两组治疗前后储尿期症状评分(USPSS)、排尿期症状评分(VSS)、膀胱过度活动症自我评价量表(OABSS)评分、国际前列腺症状(IPSS)评分改变情况,监测两组治疗前后尿流动力学参数改变,并评估两组用药安全性。结果:治疗后,观察组USPSS、VSS、OABSS和IPSS评分显著低于对照组,两组比较有统计学意义(P<0.05)。治疗后:观察组残余尿量显著低于对照组,两组比较有统计学差异(P<0.05);观察组最大尿流率(Qmax)、平均尿流率(Qave)、尿量(VV)参数水平显著高于对照组,两组比较有统计学差异(P<0.05)。观察组不良反应发生率(17.65%)与对照组(20.59%)比较,无统计学差异(P>0.05)。结论:轻中度良性前列腺增生合并膀胱过度活动症患者采用坦索罗辛联合索利那新治疗方案临床疗效可靠,临床症状改善效果较好,且不良反应风险较低。

Objective:To investigate the efficacy and safety of tamsulosin combined with solifenacin in the treatment of mild and moderate benign prostatic hyperplasia complicated with overactive bladder(OAB). Methods:68 cases of patient with mild and moderate benign prostatic hyperplasia complicated with overactive bladder were enrolled in our hospital from June 2015 to October 2016. They were randomly divided into control group and observation group, 34 for each. The observation group was administrated tamsulosin(0.2 mg, qd) combined with solifenacin(0.5 mg, qd) treatment, the control group was only administrated tamsulosin(0.2 mg, qd)treatment. The indicators including urine storage period symptom scores(USPSS), voiding symptom score(VSS), overactive bladder symptom score(OABSS), and international prostate symptom score(IPSS) were observed before and after treatment. Hemodynamics parameters were monitored before and after treatment in both groups, and the safety was also evaluated. Results:After treatment, the scores of USPSS, VSS, OABSS and IPSS in observation group were significantly lower than those in control group(P<0.05), the residual urine volume of observation group was significantly lower than that of control group and the difference between two groups was significant(P<0.05). The parameters including Qmax, Qave and VV of observation group were significantly higher than those of control group, and with no significant difference between the observation group(17.65%) and the control group(20.59%) in adverse reactions(P>0.05). Conclusion:The clinical efficacy of tamsulosin combined with solifenacin in patients with mild and moderate benign prostatic hyperplasia complicated with bladder hyperactivity is reliable, with better improving in the clinical symptoms. The risk of adverse reactions is lower, and the clinical application is effective.